Loading…
Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects
Vaccines impact antibiotic-resistant infections in two ways: through a direct reduction in the organisms and strains carrying resistant genes that are specifically targeted by the vaccine and also via a secondary effect through a reduction in febrile illnesses that often lead to the use of antibioti...
Saved in:
Published in: | Proceedings of the National Academy of Sciences - PNAS 2018-12, Vol.115 (51), p.12896-12901 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3 |
---|---|
cites | cdi_FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3 |
container_end_page | 12901 |
container_issue | 51 |
container_start_page | 12896 |
container_title | Proceedings of the National Academy of Sciences - PNAS |
container_volume | 115 |
creator | Klugman, Keith P. Black, Steven |
description | Vaccines impact antibiotic-resistant infections in two ways: through a direct reduction in the organisms and strains carrying resistant genes that are specifically targeted by the vaccine and also via a secondary effect through a reduction in febrile illnesses that often lead to the use of antibiotics. We review here the impact of pneumococcal conjugate vaccines (PCVs) on the prevalence of antibiotic-resistant disease and antibiotic usage as an example of the direct effect of vaccines on antibiotic resistance and the impact of influenza vaccination on antibiotic usage as an example of a secondary effect. A prelicensure study of a PCV in Africa demonstrated 67% fewer penicillin-resistant invasive disease episodes in the PCV group compared with controls. Similar studies in the United States and Europe demonstrated reductions in antibiotic use consistent with the vaccines’ impact on the risk of otitis media infections in children. Postlicensure reductions in the circulation of antibiotic-resistant strains targeted by the vaccines have been dramatic, with virtual elimination of these strains in children following vaccine introduction. In terms of a secondary effect, following influenza vaccination reductions of 13–50% have been observed in the use of antibiotics by individuals receiving influenza vaccine compared with controls. With the demonstrated effectiveness of vaccination programs in impacting the risk of antibiotic-resistant infections and the increasing threat to public health that these infections represent, more attention needs to be given to development and utilization of vaccines to address antibiotic resistance. |
doi_str_mv | 10.1073/pnas.1721095115 |
format | article |
fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6304973</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>26574194</jstor_id><sourcerecordid>26574194</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3</originalsourceid><addsrcrecordid>eNpdkctLAzEQxoMoWh9nT8qCFy9rJ8lmkxwURHyB4EXPIU0TTWmTmuyK_vemtNbHaYaZ33x8w4fQIYYzDJwO50HnM8wJBskwZhtoUDpct42ETTQAILwWDWl20G7OE4BCCdhGOxQYk1iyATq_n8216aroKvvhc-fDS_WujfHB5sqHKtlxbxZDHTo_8rHzpsxyIXUwdh9tOT3N9mBV99DzzfXT1V398Hh7f3X5UBsGsqudNCCkM1Q3XGIhKba8bThhY3CaWtlKYrlwWAMheiRbJ4EK4gQ1lgggY7qHLpa68340s2NjQ5f0VM2Tn-n0qaL26u8m-Ff1Et9VS6GRnBaB05VAim-9zZ2a-WzsdKqDjX1WBDNBijlKCnryD53EPoXyXqFa4JhLAoUaLimTYs7JurUZDGoRjVpEo36iKRfHv39Y899ZFOBoCUxyF9N6T1rGGywb-gW6JZOJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2160717920</pqid></control><display><type>article</type><title>Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects</title><source>JSTOR Archival Journals and Primary Sources Collection【Remote access available】</source><source>PubMed Central</source><creator>Klugman, Keith P. ; Black, Steven</creator><creatorcontrib>Klugman, Keith P. ; Black, Steven</creatorcontrib><description>Vaccines impact antibiotic-resistant infections in two ways: through a direct reduction in the organisms and strains carrying resistant genes that are specifically targeted by the vaccine and also via a secondary effect through a reduction in febrile illnesses that often lead to the use of antibiotics. We review here the impact of pneumococcal conjugate vaccines (PCVs) on the prevalence of antibiotic-resistant disease and antibiotic usage as an example of the direct effect of vaccines on antibiotic resistance and the impact of influenza vaccination on antibiotic usage as an example of a secondary effect. A prelicensure study of a PCV in Africa demonstrated 67% fewer penicillin-resistant invasive disease episodes in the PCV group compared with controls. Similar studies in the United States and Europe demonstrated reductions in antibiotic use consistent with the vaccines’ impact on the risk of otitis media infections in children. Postlicensure reductions in the circulation of antibiotic-resistant strains targeted by the vaccines have been dramatic, with virtual elimination of these strains in children following vaccine introduction. In terms of a secondary effect, following influenza vaccination reductions of 13–50% have been observed in the use of antibiotics by individuals receiving influenza vaccine compared with controls. With the demonstrated effectiveness of vaccination programs in impacting the risk of antibiotic-resistant infections and the increasing threat to public health that these infections represent, more attention needs to be given to development and utilization of vaccines to address antibiotic resistance.</description><identifier>ISSN: 0027-8424</identifier><identifier>EISSN: 1091-6490</identifier><identifier>DOI: 10.1073/pnas.1721095115</identifier><identifier>PMID: 30559195</identifier><language>eng</language><publisher>United States: National Academy of Sciences</publisher><subject>Antibiotic resistance ; Antibiotics ; Bacterial infections ; Bacterial Infections - epidemiology ; Bacterial Infections - prevention & control ; Biological Sciences ; Children ; Direct reduction ; Disease control ; Drug resistance ; Drug Resistance, Bacterial - drug effects ; Humans ; Illnesses ; Influenza ; Influenza Vaccines - therapeutic use ; Medical technology ; Otitis media ; Penicillin ; Pneumococcal Infections - epidemiology ; Pneumococcal Infections - prevention & control ; Pneumococcal Vaccines - therapeutic use ; Public health ; Side effects ; South Africa - epidemiology ; SPECIAL FEATURE: PERSPECTIVE ; Strains (organisms) ; Vaccines</subject><ispartof>Proceedings of the National Academy of Sciences - PNAS, 2018-12, Vol.115 (51), p.12896-12901</ispartof><rights>Volumes 1–89 and 106–115, copyright as a collective work only; author(s) retains copyright to individual articles</rights><rights>Copyright National Academy of Sciences Dec 18, 2018</rights><rights>2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3</citedby><cites>FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/26574194$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/26574194$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792,58237,58470</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30559195$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Klugman, Keith P.</creatorcontrib><creatorcontrib>Black, Steven</creatorcontrib><title>Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects</title><title>Proceedings of the National Academy of Sciences - PNAS</title><addtitle>Proc Natl Acad Sci U S A</addtitle><description>Vaccines impact antibiotic-resistant infections in two ways: through a direct reduction in the organisms and strains carrying resistant genes that are specifically targeted by the vaccine and also via a secondary effect through a reduction in febrile illnesses that often lead to the use of antibiotics. We review here the impact of pneumococcal conjugate vaccines (PCVs) on the prevalence of antibiotic-resistant disease and antibiotic usage as an example of the direct effect of vaccines on antibiotic resistance and the impact of influenza vaccination on antibiotic usage as an example of a secondary effect. A prelicensure study of a PCV in Africa demonstrated 67% fewer penicillin-resistant invasive disease episodes in the PCV group compared with controls. Similar studies in the United States and Europe demonstrated reductions in antibiotic use consistent with the vaccines’ impact on the risk of otitis media infections in children. Postlicensure reductions in the circulation of antibiotic-resistant strains targeted by the vaccines have been dramatic, with virtual elimination of these strains in children following vaccine introduction. In terms of a secondary effect, following influenza vaccination reductions of 13–50% have been observed in the use of antibiotics by individuals receiving influenza vaccine compared with controls. With the demonstrated effectiveness of vaccination programs in impacting the risk of antibiotic-resistant infections and the increasing threat to public health that these infections represent, more attention needs to be given to development and utilization of vaccines to address antibiotic resistance.</description><subject>Antibiotic resistance</subject><subject>Antibiotics</subject><subject>Bacterial infections</subject><subject>Bacterial Infections - epidemiology</subject><subject>Bacterial Infections - prevention & control</subject><subject>Biological Sciences</subject><subject>Children</subject><subject>Direct reduction</subject><subject>Disease control</subject><subject>Drug resistance</subject><subject>Drug Resistance, Bacterial - drug effects</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Influenza</subject><subject>Influenza Vaccines - therapeutic use</subject><subject>Medical technology</subject><subject>Otitis media</subject><subject>Penicillin</subject><subject>Pneumococcal Infections - epidemiology</subject><subject>Pneumococcal Infections - prevention & control</subject><subject>Pneumococcal Vaccines - therapeutic use</subject><subject>Public health</subject><subject>Side effects</subject><subject>South Africa - epidemiology</subject><subject>SPECIAL FEATURE: PERSPECTIVE</subject><subject>Strains (organisms)</subject><subject>Vaccines</subject><issn>0027-8424</issn><issn>1091-6490</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdkctLAzEQxoMoWh9nT8qCFy9rJ8lmkxwURHyB4EXPIU0TTWmTmuyK_vemtNbHaYaZ33x8w4fQIYYzDJwO50HnM8wJBskwZhtoUDpct42ETTQAILwWDWl20G7OE4BCCdhGOxQYk1iyATq_n8216aroKvvhc-fDS_WujfHB5sqHKtlxbxZDHTo_8rHzpsxyIXUwdh9tOT3N9mBV99DzzfXT1V398Hh7f3X5UBsGsqudNCCkM1Q3XGIhKba8bThhY3CaWtlKYrlwWAMheiRbJ4EK4gQ1lgggY7qHLpa68340s2NjQ5f0VM2Tn-n0qaL26u8m-Ff1Et9VS6GRnBaB05VAim-9zZ2a-WzsdKqDjX1WBDNBijlKCnryD53EPoXyXqFa4JhLAoUaLimTYs7JurUZDGoRjVpEo36iKRfHv39Y899ZFOBoCUxyF9N6T1rGGywb-gW6JZOJ</recordid><startdate>20181218</startdate><enddate>20181218</enddate><creator>Klugman, Keith P.</creator><creator>Black, Steven</creator><general>National Academy of Sciences</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181218</creationdate><title>Impact of existing vaccines in reducing antibiotic resistance</title><author>Klugman, Keith P. ; Black, Steven</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antibiotic resistance</topic><topic>Antibiotics</topic><topic>Bacterial infections</topic><topic>Bacterial Infections - epidemiology</topic><topic>Bacterial Infections - prevention & control</topic><topic>Biological Sciences</topic><topic>Children</topic><topic>Direct reduction</topic><topic>Disease control</topic><topic>Drug resistance</topic><topic>Drug Resistance, Bacterial - drug effects</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Influenza</topic><topic>Influenza Vaccines - therapeutic use</topic><topic>Medical technology</topic><topic>Otitis media</topic><topic>Penicillin</topic><topic>Pneumococcal Infections - epidemiology</topic><topic>Pneumococcal Infections - prevention & control</topic><topic>Pneumococcal Vaccines - therapeutic use</topic><topic>Public health</topic><topic>Side effects</topic><topic>South Africa - epidemiology</topic><topic>SPECIAL FEATURE: PERSPECTIVE</topic><topic>Strains (organisms)</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Klugman, Keith P.</creatorcontrib><creatorcontrib>Black, Steven</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Klugman, Keith P.</au><au>Black, Steven</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects</atitle><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle><addtitle>Proc Natl Acad Sci U S A</addtitle><date>2018-12-18</date><risdate>2018</risdate><volume>115</volume><issue>51</issue><spage>12896</spage><epage>12901</epage><pages>12896-12901</pages><issn>0027-8424</issn><eissn>1091-6490</eissn><abstract>Vaccines impact antibiotic-resistant infections in two ways: through a direct reduction in the organisms and strains carrying resistant genes that are specifically targeted by the vaccine and also via a secondary effect through a reduction in febrile illnesses that often lead to the use of antibiotics. We review here the impact of pneumococcal conjugate vaccines (PCVs) on the prevalence of antibiotic-resistant disease and antibiotic usage as an example of the direct effect of vaccines on antibiotic resistance and the impact of influenza vaccination on antibiotic usage as an example of a secondary effect. A prelicensure study of a PCV in Africa demonstrated 67% fewer penicillin-resistant invasive disease episodes in the PCV group compared with controls. Similar studies in the United States and Europe demonstrated reductions in antibiotic use consistent with the vaccines’ impact on the risk of otitis media infections in children. Postlicensure reductions in the circulation of antibiotic-resistant strains targeted by the vaccines have been dramatic, with virtual elimination of these strains in children following vaccine introduction. In terms of a secondary effect, following influenza vaccination reductions of 13–50% have been observed in the use of antibiotics by individuals receiving influenza vaccine compared with controls. With the demonstrated effectiveness of vaccination programs in impacting the risk of antibiotic-resistant infections and the increasing threat to public health that these infections represent, more attention needs to be given to development and utilization of vaccines to address antibiotic resistance.</abstract><cop>United States</cop><pub>National Academy of Sciences</pub><pmid>30559195</pmid><doi>10.1073/pnas.1721095115</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0027-8424 |
ispartof | Proceedings of the National Academy of Sciences - PNAS, 2018-12, Vol.115 (51), p.12896-12901 |
issn | 0027-8424 1091-6490 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6304973 |
source | JSTOR Archival Journals and Primary Sources Collection【Remote access available】; PubMed Central |
subjects | Antibiotic resistance Antibiotics Bacterial infections Bacterial Infections - epidemiology Bacterial Infections - prevention & control Biological Sciences Children Direct reduction Disease control Drug resistance Drug Resistance, Bacterial - drug effects Humans Illnesses Influenza Influenza Vaccines - therapeutic use Medical technology Otitis media Penicillin Pneumococcal Infections - epidemiology Pneumococcal Infections - prevention & control Pneumococcal Vaccines - therapeutic use Public health Side effects South Africa - epidemiology SPECIAL FEATURE: PERSPECTIVE Strains (organisms) Vaccines |
title | Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T02%3A52%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20existing%20vaccines%20in%20reducing%20antibiotic%20resistance:%20Primary%20and%20secondary%20effects&rft.jtitle=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20-%20PNAS&rft.au=Klugman,%20Keith%20P.&rft.date=2018-12-18&rft.volume=115&rft.issue=51&rft.spage=12896&rft.epage=12901&rft.pages=12896-12901&rft.issn=0027-8424&rft.eissn=1091-6490&rft_id=info:doi/10.1073/pnas.1721095115&rft_dat=%3Cjstor_pubme%3E26574194%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2160717920&rft_id=info:pmid/30559195&rft_jstor_id=26574194&rfr_iscdi=true |